The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly

Korkmaz, Özge Polat; Gürcan, Mert; Kantarci, Fatma Eda Nuhoglu; Haliloğlu, Özlem; Özkaya, Hande Mefkure; Şahin, Serdar; Ören, Meryem Merve; Tanrıöver, Necmettin; Gazioğlu, Nurperi; Kadıoğlu, Pınar

doi:10.1007/s11102-019-00968-6

Cited by 9 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pre-surgical medical treatment significantly improved short-and long-term remission in patients with acromegaly, independently of its duration, especially in invasive adenomas [26]. There was a beneficial effect of pre-operative SSA use on early remission in macroadenomas; however, this effect did not persist in long-term observation [27].…”

Section: Discussionmentioning

confidence: 91%

Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly

Bolanowski

Zgliczyński

Sowiński

et al. 2020

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: The aim of this study was to assess the therapeutic effect and the safety of pre-surgical treatment with long-acting octreotide in patients with acromegaly. Material and methods: This project was conducted in 25 centres across Poland as a non-interventional, multicentre, observational study in patients with acromegaly, in which long-acting octreotide (Sandostatin ® LAR ®) was administered before surgery. They were 148 patients included into the study: 88 females and 60 males aged 18-86 years (51.3 ± 13.4). Results: Eighty patients completed the study (underwent tumour surgery). The CRF included: baseline visit, four follow-up visits every three months before surgery, and two follow-up visits every three months after surgery. Sandostatin ® LAR ® was administered every four weeks. The efficacy measures were as follows: change of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, number of patients fulfilling criteria of cure, and change of adenoma (micro-and macroadenomas) size during the treatment. Normalisation of GH and IGF-1 concentrations were obtained in 42.4 and 49.1% of patients at the end of medical therapy, respectively. Normalisation of GH and IGF-1 concentrations were obtained in 77.9 and 83.8% of patients after surgery, respectively. Reduction of microadenoma size was documented in 58.8% of patients, and in 70% of patients with macroadenomas at the end of medical therapy. In 74.0% of patients no pituitary tumour was shown on MRI after surgery. Conclusion: In conclusion, we have shown good surgical outcome in patients with acromegaly after pre-treatment with somatostatin analogue, and good tolerance and safety of the therapy, supporting the national recommendation for pre-surgical treatment with longacting somatostatin analogues in acromegaly patients.

show abstract

Section: Discussionmentioning

confidence: 91%

Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly

Bolanowski

Zgliczyński

Sowiński

et al. 2020

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…Randomized studies suggest improvement in postoperative remission after pretreatment with SRL for 3-6 months (MQ). However, data are conflicting and, in many instances, results were not sustained during long-term follow-up (LQ) (47)(48)(49)(50). The role of SRL pretreatment in improving anesthetic risk is not clear and current data do not support a general recommendation for preoperative SRL treatment (SR) (51).…”

Section: Preoperative Srl Therapymentioning

confidence: 99%

Multidisciplinary management of acromegaly: A consensus

Giustina

Barkhoudarian

Beckers

et al. 2020

Rev Endocr Metab Disord

229

188

View full text Add to dashboard Cite

The 13th Acromegaly Consensus Conference was held in November 2019 in Fort Lauderdale, Florida, and comprised acromegaly experts including endocrinologists and neurosurgeons who considered optimal approaches for multidisciplinary acromegaly management. Focused discussions reviewed techniques, results, and side effects of surgery, radiotherapy, and medical therapy, and how advances in technology and novel techniques have changed the way these modalities are used alone or in combination. Effects of treatment on patient outcomes were considered, along with strategies for optimizing and personalizing therapeutic approaches.Expert consensus recommendations emphasize how best to implement available treatment options as part of a multidisciplinary approach at Pituitary Tumor Centers of Excellence.

show abstract

“…As illustrated in Figure 2, five articles had a statistically significant difference between the two comparative groups 12–16 . Lanreotide might be less efficacious than octreotide as all papers comparing octreotide to nil medical therapy had significant results.…”

Section: Resultsmentioning

confidence: 99%

“…On the other hand, meta-analyses showed a statistically significant higher short-term biochemical remission of patients when given preoperative SAs with an OR of 2.07 (95% CI 1.50-2.87 p < .00001), and RR of 2.15 (95% CI 1.39-3.33), respectively 30,32 ; which is in agreement with three of the studies included in this review. 12,14,15 4.2 | Critiques of the studies concerning the surgical approach to patients with acromegaly…”

Section: Quality Assessmentmentioning

confidence: 99%

Preoperative medical treatments and surgical approaches for acromegaly: A systematic review

Papaioannou

Druce

2022

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

The effects of pre-operative somatostatin analogue therapy on treatment cost and remission in acromegaly

Cited by 9 publications

References 37 publications

Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly

Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly

Multidisciplinary management of acromegaly: A consensus

Preoperative medical treatments and surgical approaches for acromegaly: A systematic review

Contact Info

Product

Resources

About